Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
– Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial –
– Recent Positive Data Presentations Highlight the Potential Safety, Efficacy and Durability Benefits of Suprachoroidal Administration of Small Molecule Suspensions –
Related news for (CLSD)
- Biotech in Focus: Regulatory Wins, Strategic Moves, and Speculative Momentum
- Clearside Biomedical Secures Canadian Approval for XIPERE as Suprachoroidal Treatment for Uveitic Macular Edema
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/23/25 07:00 AM
- 24/7 Market News Snapshot 23 July, 2025 – Clearside Biomedical, Inc. Common Stock (NASDAQ:CLSD)
- Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada